Form 4: DexCom Director Euan Ashley Receives RSU Grant
Statement of Changes in Beneficial Ownership
DexCom Director Euan Ashley was granted 5,565 restricted stock units as part of his annual equity compensation.
Summary
- Director Euan Ashley acquired 5,565 restricted stock units (RSUs) on May 28, 2026.
- The grant represents a contingent right to receive one share of common stock per unit upon settlement.
- The total beneficial ownership for the director following this transaction is 12,731 shares, all of which are unvested RSUs.
- The new grant is scheduled to vest on the earlier of the one-year anniversary of the grant date or the 2027 Annual Meeting of Stockholders.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event, as it represents standard director compensation rather than a strategic shift or market-moving financial development.
Positives
- Alignment of director interests with long-term shareholder value through equity-based compensation.
Negatives
- None identified; this is a standard equity compensation disclosure.
Risks
- None identified; this is a standard equity compensation disclosure.
Future Outlook
The RSU award is set to vest in full on the earlier of May 28, 2027, or the date of the 2027 Annual Meeting of Stockholders.
Management Comments
- No specific management commentary provided in this regulatory filing.
Industry Context
StockSavvy.ai notes that this filing is a routine disclosure of director compensation, which is standard practice for publicly traded companies to ensure transparency in executive and board-level equity incentives.
Comparison to Industry Standards
- The use of RSUs for director compensation is consistent with standard corporate governance practices in the medical device and technology sectors.
- The vesting schedule aligns with typical one-year cliff or annual meeting-based vesting cycles for non-employee directors.
Stakeholder Impact
- Minimal impact on shareholders as this is a routine equity grant to a board member.
Next Steps
- Vesting of the 5,565 RSUs on or before May 28, 2027.
Key Dates
| Date | Description |
|---|---|
| 2025-10-24 | Grant date of previous RSU tranche. |
| 2026-05-28 | Grant date of new RSU award. |
| 2026-06-01 | Filing date of the Form 4. |
| 2028-10-24 | Final vesting date for previous RSU tranche. |
Keywords
DexCom, DXCM, Form 4, Insider Trading, Equity Compensation, Director Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.